Oral Biologics Market Size, Share & Trends Analysis Report by Molecule Type (Peptides, Proteins & Enzymes, Vaccines (Oral), Hormones, Nucleic Acid-based Biologics, Live Biotherapeutic Products, Other Types), Delivery Technology, Dosage Form, Therapeutic Area, Indication, End User and Geography (North America, Europe, Asia Pacific, Middle East, Africa and South America) – Global Industry Data, Trends and Forecasts, 2026–2035
Market Overview:
As per MarketGenics, the global Oral Biologics Market is experiencing significant growth, valued at USD 3.7 billion in 2025 and projected to reach USD 16.9 billion by 2035, registering a CAGR of 16.4% during the forecast period.
|
|
|
Segmental Data Insights |
|
|
Demand Trends |
|
|
Competitive Landscape |
|
|
Strategic Development |
|
|
Future Outlook & Opportunities |
|
Oral Biologics Market Size, Share, and Growth
“Making biologics oral has been one of the most difficult challenges in drug delivery,” said Thomas von Erlach, Ph.D., CEO and co-founder of Vivtex. “Vivtex was founded to systematically solve this problem by integrating high-throughput experimentation with computational and AI-enabled analytics. Partnering with Novo Nordisk allows us to apply our platform across important metabolic disease areas, with the goal of enabling oral therapies that would otherwise require injection.”
The rising patient adoption of oral GLP-1s is fueling a demand for convenient, non-invasive treatments over injectable biologic therapies. For instance, in April 2026, Eli Lilly’s Foundayo (orforglipron) received FDA approval as a once-daily oral GLP-1 therapy for adults with obesity or overweight with weight-related comorbidities. Increased access to once daily oral GLP-1, which is likely to increase patient adoption, is likely to open up the commercial opportunity for oral biologics.
Additionally, the growing pipeline of oral biologic drugs is fueling the oral-biologics-market growth by diversifying the therapeutic application and boosting innovation. For instance, in June 2026, Pfizer advanced berobenatide, a GLP-1 receptor agonist, toward Phase 3 development following positive Phase 2b results, supporting continued innovation in oral biologics
Adjacent opportunities for the global oral biologics market include oral peptide drug delivery, device-enabled oral delivery, oral nucleic acid delivery, oral insulin delivery, microbiome-based oral biologics. Growth into additional delivery technologies may expand therapeutic opportunities, drive innovation and enhance the market potential of oral biologics.
Oral Biologics Market Dynamics and Trends
Driver: FDA Approvals Accelerating Adoption of Convenient Oral Biologic Therapies
- FDA approvals are accelerating adoption of convenient oral biologic therapies by validating their clinical efficacy, safety, and manufacturing feasibility. Regulatory acceptance is a key component of lowering uncertainty in development and enhancing the pharma investment in oral delivery platforms.
- The increasing awareness of oral administration as an alternative to injected therapies that is more patient-friendlier is driving innovation in the development of peptides and protein-based formulations. These advances can enhance treatment adherence, increase patient acceptance, and facilitate greater commercialization of oral biologics outside of the limited chronic disease category.
- For instance, in July 2026, Merck received the U.S. FDA approval for the first once-daily oral PCSK9 inhibitor, LIPFENDRA (enlicitide), following two Phase 3 clinical trials, CORALreef, which showed LDL-C reductions of 56% and 59% with LIPFENDRA compared to placebo in hypercholesterolemia and HeFH, respectively.
- Regulatory approvals are driving market confidence, driving innovation and increasing the commercial opportunities of oral biological therapies
Restraint: Gastrointestinal Degradation and Limited Absorption Constrain Effective Oral Biologic Delivery
- Oral biologics face substantial formulation and physiological barriers because proteins and peptides can be degraded by gastric acid and digestive enzymes before reaching systemic circulation. By virtue of their large molecular structure they are also not easily penetrable and often have low and variable bioavailability.
- These challenges can involve using higher doses or special delivery technologies, adding complexity to the formulations, increasing manufacturing costs, lengthening development times and drug regulatory uncertainty when compared to conventional injectable administration. Also, gastrointestinal conditions vary, influencing drug absorption and therapeutic consistency.
- Barriers for delivery and absorption may lead to higher development expenses and limited use of oral biologic therapies.
Opportunity: Advanced Peptide Manufacturing Capacity Creates Opportunities for Scalable Oral Biologics Production
- The expansion of specialized peptide manufacturing infrastructure can enhance production capacity, supply reliability, process consistency, and commercialization readiness in the oral biologics sector.
- Pharma companies are developing oral peptide drugs, which is driving a growing demand for specialized skills for peptide synthesis, purification, analytical testing, formulation, and large-scale production.
- These capabilities can be enhanced through strategic investment and acquisition and help to minimize reliance on disjointed supply chains. For instance, in July 2026, Samsung Biologics announced an approximately $1.8 billion acquisition of PolyPeptide Group, strengthening global peptide manufacturing capabilities across key markets.
- Increased infrastructure for peptide manufacturing has the potential to increase scalability and expedite oral biologic lead advancement.
Key Trend: Patient preference for noninjectable therapies is reshaping development toward oral biologic formulations
- The need for convenient, non-injection treatment options is driving pharmaceutical companies to focus on OMs that are easier to take and may drive increased treatment uptake.
- Oral delivery may minimize reliance on injection devices, injection training, and health care provider involvement, which can be very advantageous for the management of chronic disease.
- This trend is spurring companies to invest in formulation technologies that can achieve biologic stability and therapeutic exposure after oral delivery. For instance, in July 2026, Novo Nordisk obtained European approval for the oral semaglutide drug, Wegovy, administered once a day, representing a shift the industry is making toward more patient-centric biologic delivery options, delivering both therapeutic efficacy and increased convenience.
- Growing preference for noninjectable treatments is driving a shift in biologic innovation toward convenient, patient-centric oral delivery formats.
Oral Biologics Market Analysis and Segmental Data
Peptides Dominate Global Oral Biologics Market
- The peptides segment dominates the global oral biologics market due to their smaller molecular size and ease of chemical modification when compared to larger protein-based biologics, which are more suitable for oral delivery. The development of peptide formulations, its permeability, and gastrointestinal protection are improving, furthering the peptide development in metabolic and chronic diseases.
- For instance, in February 2026, Novo Nordisk joined forces with Vivtex to develop next generation oral drugs for obesity and diabetes based on technologies to enhance the oral bioavailability of peptide and protein drug products.
- The introduction of new peptides and formulation advancements continues to bolster peptides as an important growth segment of the oral biologics market.
North America Leads Global Oral Biologics Market Demand
- North America leads the oral biologics market is due to the presence of a well-established biopharmaceutical ecosystem in the region, the advanced clinical infrastructure, high R&D investments, and robust commercialization capacity to develop and commercialize oral biologic products.
- In addition, U.S. government programs are advancing the development landscape for oral peptides by providing regulatory guidance and science review. For instance, in July 2026, the FDA’s Center for Research on Complex Generics scheduled a workshop addressing oral peptide formulations, absorption-enhancement technologies, and bioequivalence approaches, reflecting increasing regulatory attention toward oral peptide development.
- North America's oral biologic innovation and market leadership continue to be supported by strong pharmaceutical capabilities and government-backed regulatory environment.
Oral Biologics Market Ecosystem
The global oral biologics market is moderately consolidated, with Novo Nordisk, Eli Lilly and Company, AstraZeneca, Pfizer, and Sanofi maintaining strong positions through advanced peptide engineering, oral drug-delivery technologies, formulation platforms, and biologics development capabilities.
Specialized oral peptide and protein drug development is a growing focus for leading companies targeted for metabolic, cardiovascular and chronic disease, aided by absorption-enhancement technologies, molecular optimization and controlled-release formulations.
Key Pharma firms are also focusing on portfolios diversification and integrated development capabilities, including discovery, formulation, clinical development, manufacturing, and commercialization, to enhance development efficiency and broaden therapeutic applications. Also, companies are developing oral versions of existing injectable biologics to improve patient convenience and improve adherence.
Innovation, efficiency in development and increased adoption of oral biologic treatments is gaining speed due to strong industry capabilities and rapid portfolio expansion.
Recent Development and Strategic Overview:
- In July 2026, Rani Therapeutics reported Phase 1a data for oral RT-114, achieving over 150% systemic exposure versus matched subcutaneous PG-102, supporting the RaniPill platform for oral biologic delivery.
- In June 2026, AstraZeneca advanced elecoglipron, an oral small-molecule GLP-1 receptor agonist, into Phase III after Phase IIb trials achieved 11.8% weight loss and 1.9% HbA1c reduction, supporting oral treatment development for obesity and type 2 diabetes.
Report Scope
|
Detail |
|
|
Market Size in 2025 |
USD 3.7 Bn |
|
Market Forecast Value in 2035 |
USD 16.9 Bn |
|
Growth Rate (CAGR) |
16.4% |
|
Forecast Period |
2026 – 2035 |
|
Historical Data Available for |
2021 – 2024 |
|
Market Size Units |
US$ Billion for Value |
|
Report Format |
Electronic (PDF) + Excel |
|
North America |
Europe |
Asia Pacific |
Middle East |
Africa |
South America |
|
|
|
|
|
|
|
Companies Covered |
|||||
|
|
|||||
Oral Biologics Market Segmentation and Highlights
|
Segment |
Sub-segment |
|
Oral Biologics Market, By Molecule Type |
|
|
Oral Biologics Market, By Delivery Technology |
|
|
Oral Biologics Market, By Dosage Form |
|
|
Oral Biologics Market, By Therapeutic Area |
|
|
Oral Biologics Market, By Indication |
|
|
Oral Biologics Market, By End User |
|
Frequently Asked Questions
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Oral Biologics Market Outlook
- 2.1.1. Oral Biologics Market Size (Value - US$ Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2026-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global Oral Biologics Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Rising preference for convenient, needle-free administration of biologic therapies
- 4.1.1.2. Advances in drug delivery technologies improve oral biologic absorption
- 4.1.1.3. Growing development of oral peptide and protein therapies expands opportunities
- 4.1.2. Restraints
- 4.1.2.1. Gastrointestinal degradation limits oral bioavailability of biologic drugs.
- 4.1.2.2. Complex formulations increase development costs and regulatory challenges
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global Oral Biologics Market Demand
- 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
- 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
- 4.7.2.1. Y-o-Y Growth Trends
- 4.7.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global Oral Biologics Market Analysis, by Molecule Type
- 6.1. Key Segment Analysis
- 6.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Molecule Type, 2021-2035
- 6.2.1. Peptides
- 6.2.2. Proteins & Enzymes
- 6.2.3. Vaccines (Oral)
- 6.2.4. Hormones
- 6.2.5. Nucleic Acid-based Biologics
- 6.2.6. Live Biotherapeutic Products
- 6.2.7. Other Types
- 7. Global Oral Biologics Market Analysis, by Delivery Technology
- 7.1. Key Segment Analysis
- 7.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Delivery Technology, 2021-2035
- 7.2.1. Permeation Enhancer-based Systems
- 7.2.2. Enteric Coating Technologies
- 7.2.3. Lipid-based Nanocarriers
- 7.2.4. Polymer-based Nanoparticle Carriers
- 7.2.5. Micro-injector Oral Devices
- 7.2.6. Hydrogel & Mucoadhesive Systems
- 7.2.7. Protease Inhibitor-based Formulations
- 7.2.8. Cell-penetrating Peptide Conjugates
- 7.2.9. Other Technologies
- 8. Global Oral Biologics Market Analysis, by Dosage Form
- 8.1. Key Segment Analysis
- 8.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Dosage Form, 2021-2035
- 8.2.1. Tablets
- 8.2.2. Capsules
- 8.2.3. Oral Films
- 8.2.4. Oral Suspensions
- 8.2.5. Powders for Reconstitution
- 9. Global Oral Biologics Market Analysis, by Therapeutic Area
- 9.1. Key Segment Analysis
- 9.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
- 9.2.1. Diabetes (Oral Insulin, GLP-1 analogs)
- 9.2.2. Autoimmune & Inflammatory Diseases
- 9.2.3. Gastrointestinal Disorders
- 9.2.4. Oncology
- 9.2.5. Infectious Diseases
- 9.2.6. Hormonal/Endocrine Disorders
- 9.2.7. Cardiovascular Diseases
- 9.2.8. Osteoporosis & Bone Disorders
- 9.2.9. Others
- 10. Global Oral Biologics Market Analysis, by Indication
- 10.1. Key Segment Analysis
- 10.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Indication, 2021-2035
- 10.2.1. Chronic Disease Management
- 10.2.2. Acute Care
- 10.2.3. Preventive/Prophylactic Use
- 11. Global Oral Biologics Market Analysis, by End User
- 11.1. Key Segment Analysis
- 11.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
- 11.2.1. Hospitals
- 11.2.2. Specialty Clinics
- 11.2.3. Homecare Settings
- 11.2.4. Academic & Research Institutes
- 11.2.5. CROs/ CDMOs
- 12. Global Oral Biologics Market Analysis, by Region
- 12.1. Key Findings
- 12.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
- 12.2.1. North America
- 12.2.2. Europe
- 12.2.3. Asia Pacific
- 12.2.4. Middle East
- 12.2.5. Africa
- 12.2.6. South America
- 13. North America Oral Biologics Market Analysis
- 13.1. Key Segment Analysis
- 13.2. Regional Snapshot
- 13.3. North America Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 13.3.1. Molecule Type
- 13.3.2. Delivery Technology
- 13.3.3. Dosage Form
- 13.3.4. Therapeutic Area
- 13.3.5. Indication
- 13.3.6. End User
- 13.3.7. Country
- 13.3.7.1. USA
- 13.3.7.2. Canada
- 13.3.7.3. Mexico
- 13.4. USA Oral Biologics Market
- 13.4.1. Country Segmental Analysis
- 13.4.2. Molecule Type
- 13.4.3. Delivery Technology
- 13.4.4. Dosage Form
- 13.4.5. Therapeutic Area
- 13.4.6. Indication
- 13.4.7. End User
- 13.5. Canada Oral Biologics Market
- 13.5.1. Country Segmental Analysis
- 13.5.2. Molecule Type
- 13.5.3. Delivery Technology
- 13.5.4. Dosage Form
- 13.5.5. Therapeutic Area
- 13.5.6. Indication
- 13.5.7. End User
- 13.6. Mexico Oral Biologics Market
- 13.6.1. Country Segmental Analysis
- 13.6.2. Molecule Type
- 13.6.3. Delivery Technology
- 13.6.4. Dosage Form
- 13.6.5. Therapeutic Area
- 13.6.6. Indication
- 13.6.7. End User
- 14. Europe Oral Biologics Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. Europe Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 14.3.1. Molecule Type
- 14.3.2. Delivery Technology
- 14.3.3. Dosage Form
- 14.3.4. Therapeutic Area
- 14.3.5. Indication
- 14.3.6. End User
- 14.3.7. Country
- 14.3.7.1. Germany
- 14.3.7.2. United Kingdom
- 14.3.7.3. France
- 14.3.7.4. Italy
- 14.3.7.5. Spain
- 14.3.7.6. Netherlands
- 14.3.7.7. Nordic Countries
- 14.3.7.8. Poland
- 14.3.7.9. Russia & CIS
- 14.3.7.10. Rest of Europe
- 14.4. Germany Oral Biologics Market
- 14.4.1. Country Segmental Analysis
- 14.4.2. Molecule Type
- 14.4.3. Delivery Technology
- 14.4.4. Dosage Form
- 14.4.5. Therapeutic Area
- 14.4.6. Indication
- 14.4.7. End User
- 14.5. United Kingdom Oral Biologics Market
- 14.5.1. Country Segmental Analysis
- 14.5.2. Molecule Type
- 14.5.3. Delivery Technology
- 14.5.4. Dosage Form
- 14.5.5. Therapeutic Area
- 14.5.6. Indication
- 14.5.7. End User
- 14.6. France Oral Biologics Market
- 14.6.1. Country Segmental Analysis
- 14.6.2. Molecule Type
- 14.6.3. Delivery Technology
- 14.6.4. Dosage Form
- 14.6.5. Therapeutic Area
- 14.6.6. Indication
- 14.6.7. End User
- 14.7. Italy Oral Biologics Market
- 14.7.1. Country Segmental Analysis
- 14.7.2. Molecule Type
- 14.7.3. Delivery Technology
- 14.7.4. Dosage Form
- 14.7.5. Therapeutic Area
- 14.7.6. Indication
- 14.7.7. End User
- 14.8. Spain Oral Biologics Market
- 14.8.1. Country Segmental Analysis
- 14.8.2. Molecule Type
- 14.8.3. Delivery Technology
- 14.8.4. Dosage Form
- 14.8.5. Therapeutic Area
- 14.8.6. Indication
- 14.8.7. End User
- 14.9. Netherlands Oral Biologics Market
- 14.9.1. Country Segmental Analysis
- 14.9.2. Molecule Type
- 14.9.3. Delivery Technology
- 14.9.4. Dosage Form
- 14.9.5. Therapeutic Area
- 14.9.6. Indication
- 14.9.7. End User
- 14.10. Nordic Countries Oral Biologics Market
- 14.10.1. Country Segmental Analysis
- 14.10.2. Molecule Type
- 14.10.3. Delivery Technology
- 14.10.4. Dosage Form
- 14.10.5. Therapeutic Area
- 14.10.6. Indication
- 14.10.7. End User
- 14.11. Poland Oral Biologics Market
- 14.11.1. Country Segmental Analysis
- 14.11.2. Molecule Type
- 14.11.3. Delivery Technology
- 14.11.4. Dosage Form
- 14.11.5. Therapeutic Area
- 14.11.6. Indication
- 14.11.7. End User
- 14.12. Russia & CIS Oral Biologics Market
- 14.12.1. Country Segmental Analysis
- 14.12.2. Molecule Type
- 14.12.3. Delivery Technology
- 14.12.4. Dosage Form
- 14.12.5. Therapeutic Area
- 14.12.6. Indication
- 14.12.7. End User
- 14.13. Rest of Europe Oral Biologics Market
- 14.13.1. Country Segmental Analysis
- 14.13.2. Molecule Type
- 14.13.3. Delivery Technology
- 14.13.4. Dosage Form
- 14.13.5. Therapeutic Area
- 14.13.6. Indication
- 14.13.7. End User
- 15. Asia Pacific Oral Biologics Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Asia Pacific Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Molecule Type
- 15.3.2. Delivery Technology
- 15.3.3. Dosage Form
- 15.3.4. Therapeutic Area
- 15.3.5. Indication
- 15.3.6. End User
- 15.3.7. Country
- 15.3.7.1. China
- 15.3.7.2. India
- 15.3.7.3. Japan
- 15.3.7.4. South Korea
- 15.3.7.5. Australia and New Zealand
- 15.3.7.6. Indonesia
- 15.3.7.7. Malaysia
- 15.3.7.8. Thailand
- 15.3.7.9. Vietnam
- 15.3.7.10. Rest of Asia Pacific
- 15.4. China Oral Biologics Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Molecule Type
- 15.4.3. Delivery Technology
- 15.4.4. Dosage Form
- 15.4.5. Therapeutic Area
- 15.4.6. Indication
- 15.4.7. End User
- 15.5. India Oral Biologics Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Molecule Type
- 15.5.3. Delivery Technology
- 15.5.4. Dosage Form
- 15.5.5. Therapeutic Area
- 15.5.6. Indication
- 15.5.7. End User
- 15.6. Japan Oral Biologics Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Molecule Type
- 15.6.3. Delivery Technology
- 15.6.4. Dosage Form
- 15.6.5. Therapeutic Area
- 15.6.6. Indication
- 15.6.7. End User
- 15.7. South Korea Oral Biologics Market
- 15.7.1. Country Segmental Analysis
- 15.7.2. Molecule Type
- 15.7.3. Delivery Technology
- 15.7.4. Dosage Form
- 15.7.5. Therapeutic Area
- 15.7.6. Indication
- 15.7.7. End User
- 15.8. Australia and New Zealand Oral Biologics Market
- 15.8.1. Country Segmental Analysis
- 15.8.2. Molecule Type
- 15.8.3. Delivery Technology
- 15.8.4. Dosage Form
- 15.8.5. Therapeutic Area
- 15.8.6. Indication
- 15.8.7. End User
- 15.9. Indonesia Oral Biologics Market
- 15.9.1. Country Segmental Analysis
- 15.9.2. Molecule Type
- 15.9.3. Delivery Technology
- 15.9.4. Dosage Form
- 15.9.5. Therapeutic Area
- 15.9.6. Indication
- 15.9.7. End User
- 15.10. Malaysia Oral Biologics Market
- 15.10.1. Country Segmental Analysis
- 15.10.2. Molecule Type
- 15.10.3. Delivery Technology
- 15.10.4. Dosage Form
- 15.10.5. Therapeutic Area
- 15.10.6. Indication
- 15.10.7. End User
- 15.11. Thailand Oral Biologics Market
- 15.11.1. Country Segmental Analysis
- 15.11.2. Molecule Type
- 15.11.3. Delivery Technology
- 15.11.4. Dosage Form
- 15.11.5. Therapeutic Area
- 15.11.6. Indication
- 15.11.7. End User
- 15.12. Vietnam Oral Biologics Market
- 15.12.1. Country Segmental Analysis
- 15.12.2. Molecule Type
- 15.12.3. Delivery Technology
- 15.12.4. Dosage Form
- 15.12.5. Therapeutic Area
- 15.12.6. Indication
- 15.12.7. End User
- 15.13. Rest of Asia Pacific Oral Biologics Market
- 15.13.1. Country Segmental Analysis
- 15.13.2. Molecule Type
- 15.13.3. Delivery Technology
- 15.13.4. Dosage Form
- 15.13.5. Therapeutic Area
- 15.13.6. Indication
- 15.13.7. End User
- 16. Middle East Oral Biologics Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Middle East Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Molecule Type
- 16.3.2. Delivery Technology
- 16.3.3. Dosage Form
- 16.3.4. Therapeutic Area
- 16.3.5. Indication
- 16.3.6. End User
- 16.3.7. Country
- 16.3.7.1. Turkey
- 16.3.7.2. UAE
- 16.3.7.3. Saudi Arabia
- 16.3.7.4. Israel
- 16.3.7.5. Rest of Middle East
- 16.4. Turkey Oral Biologics Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Molecule Type
- 16.4.3. Delivery Technology
- 16.4.4. Dosage Form
- 16.4.5. Therapeutic Area
- 16.4.6. Indication
- 16.4.7. End User
- 16.5. UAE Oral Biologics Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Molecule Type
- 16.5.3. Delivery Technology
- 16.5.4. Dosage Form
- 16.5.5. Therapeutic Area
- 16.5.6. Indication
- 16.5.7. End User
- 16.6. Saudi Arabia Oral Biologics Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Molecule Type
- 16.6.3. Delivery Technology
- 16.6.4. Dosage Form
- 16.6.5. Therapeutic Area
- 16.6.6. Indication
- 16.6.7. End User
- 16.7. Israel Oral Biologics Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Molecule Type
- 16.7.3. Delivery Technology
- 16.7.4. Dosage Form
- 16.7.5. Therapeutic Area
- 16.7.6. Indication
- 16.7.7. End User
- 16.8. Rest of Middle East Oral Biologics Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Molecule Type
- 16.8.3. Delivery Technology
- 16.8.4. Dosage Form
- 16.8.5. Therapeutic Area
- 16.8.6. Indication
- 16.8.7. End User
- 17. Africa Oral Biologics Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Africa Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Molecule Type
- 17.3.2. Delivery Technology
- 17.3.3. Dosage Form
- 17.3.4. Therapeutic Area
- 17.3.5. Indication
- 17.3.6. End User
- 17.3.7. Country
- 17.3.7.1. South Africa
- 17.3.7.2. Egypt
- 17.3.7.3. Nigeria
- 17.3.7.4. Algeria
- 17.3.7.5. Rest of Africa
- 17.4. South Africa Oral Biologics Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Molecule Type
- 17.4.3. Delivery Technology
- 17.4.4. Dosage Form
- 17.4.5. Therapeutic Area
- 17.4.6. Indication
- 17.4.7. End User
- 17.5. Egypt Oral Biologics Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Molecule Type
- 17.5.3. Delivery Technology
- 17.5.4. Dosage Form
- 17.5.5. Therapeutic Area
- 17.5.6. Indication
- 17.5.7. End User
- 17.6. Nigeria Oral Biologics Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Molecule Type
- 17.6.3. Delivery Technology
- 17.6.4. Dosage Form
- 17.6.5. Therapeutic Area
- 17.6.6. Indication
- 17.6.7. End User
- 17.7. Algeria Oral Biologics Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Molecule Type
- 17.7.3. Delivery Technology
- 17.7.4. Dosage Form
- 17.7.5. Therapeutic Area
- 17.7.6. Indication
- 17.7.7. End User
- 17.8. Rest of Africa Oral Biologics Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Molecule Type
- 17.8.3. Delivery Technology
- 17.8.4. Dosage Form
- 17.8.5. Therapeutic Area
- 17.8.6. Indication
- 17.8.7. End User
- 18. South America Oral Biologics Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. South America Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Molecule Type
- 18.3.2. Delivery Technology
- 18.3.3. Dosage Form
- 18.3.4. Therapeutic Area
- 18.3.5. Indication
- 18.3.6. End User
- 18.3.7. Country
- 18.3.7.1. Brazil
- 18.3.7.2. Argentina
- 18.3.7.3. Rest of South America
- 18.4. Brazil Oral Biologics Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Molecule Type
- 18.4.3. Delivery Technology
- 18.4.4. Dosage Form
- 18.4.5. Therapeutic Area
- 18.4.6. Indication
- 18.4.7. End User
- 18.5. Argentina Oral Biologics Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Molecule Type
- 18.5.3. Delivery Technology
- 18.5.4. Dosage Form
- 18.5.5. Therapeutic Area
- 18.5.6. Indication
- 18.5.7. End User
- 18.6. Rest of South America Oral Biologics Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Molecule Type
- 18.6.3. Delivery Technology
- 18.6.4. Dosage Form
- 18.6.5. Therapeutic Area
- 18.6.6. Indication
- 18.6.7. End User
- 19. Key Players/ Company Profile
- 19.1. AstraZeneca plc
- 19.1.1. Company Details/ Overview
- 19.1.2. Company Financials
- 19.1.3. Key Customers and Competitors
- 19.1.4. Business/ Industry Portfolio
- 19.1.5. Product Portfolio/ Specification Details
- 19.1.6. Pricing Data
- 19.1.7. Strategic Overview
- 19.1.8. Recent Developments
- 19.2. Biocon Limited
- 19.3. Chugai Pharmaceutical
- 19.4. Cyclo Therapeutics, Inc.
- 19.5. Diasome Pharmaceuticals, Inc.
- 19.6. Eli Lilly and Company
- 19.7. Entera Bio Ltd.
- 19.8. Innovent Biologics, Inc.
- 19.9. Merck & Co.
- 19.10. Novo Nordisk
- 19.11. Oramed Pharmaceuticals
- 19.12. Pfizer Inc.
- 19.13. Protagonist Therapeutics Inc.
- 19.14. Rani Therapeutics Holdings, Inc.
- 19.15. Sanofi S.A.
- 19.16. Sun Pharmaceutical Industries
- 19.17. Others
- 19.1. AstraZeneca plc
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Research Design
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
Research Approach
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
Research Methods
Desk / Secondary Research
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is a combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase, and others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players' product portfolio
Primary Research
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources include primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
Forecasting Factors and Models
Forecasting Factors
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Forecasting Models / Techniques
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Research Analysis
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Validation & Evaluation
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation